Expert Review of Anticancer Therapy

Article	Citations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	86
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	81
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma	46
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	42
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	38
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	31
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia	31
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs	31
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence	31
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	30
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	28
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	26
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes	25
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	24
Importance of radiation-related cognitive decline in older adults who receive cranial radiation	24
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	23
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	22
Progress in histology specific treatments in soft tissue sarcoma	22
Current management of familial adenomatous polyposis	21
Progress in the development of tissue-based biomarkers for urothelial cancer	19
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	18
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	18
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	17
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	16
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	16

CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	15
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	15
Early detection of hepatocellular carcinoma: roadmap for improvement	15
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	15
Determining factors of neuroplasticity in patients with brain tumors: impact of connectome and artificial intelligence. A narrative review	14
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	13
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	13
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	13
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis	12
Management of breast cancer diagnosed during pregnancy: global perspectives	12
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	12
Current status of robotic surgery for hepato-pancreato-biliary malignancies	12
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	12
Deciding individual treatment for primary retroperitoneal sarcoma	12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
The trend toward more target therapy in pancreatic ductal adenocarcinoma	12
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
Targeting GPRC5D in multiple myeloma	11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	11
Novel breakthroughs in advanced prostate cancer management	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
Nivolumab plus ipilimumab in malignant pleural mesothelioma	11
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer	11
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	11
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	11
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	11
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Pembrolizumab in the first-line treatment of advanced head and neck cancer	10
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy	10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	10
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	10
Emerging treatment options for prostate cancer	10
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	10
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	10
PROTACs in action: a novel strategy for pancreatic cancer	10
Genetic investigation in patients with histological variants of bladder cancer: clinical implications	10
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	10
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	9
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	9
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	9
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy	9
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol	9
Drugging the DNA damage response in the clinic: going beyond PARP	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	9
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	9
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials	9
Cemiplimab for locally advanced and metastatic basal cell carcinoma	9
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	9
Upper and Lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis	9

Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9
Interventions to reduce the risk of side-effects of cancer treatments in childhood	9
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty	9
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	9
Oligometastases in head and neck squamous cell carcinoma patients	9
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	9
Benign and malignant cardiac masses: long-term outcomes after surgical resection	9
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	8
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	8
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	8
Immune checkpoint inhibition in early-stage triple-negative breast cancer	8
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	8
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)	8
Venetoclax and beyond: New Horizons in CLL and AML therapy	8
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	8
Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential	8
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	8
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	8
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	8
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	7
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study	7
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	7
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	7
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	7
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	7
Circadian rhythm-based cancer therapy in randomised clinical trials	7
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	7
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	7
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	7
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	7
Medullary thyroid carcinoma: a narrative historical review	7
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	7
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	7
Primary site and treatment impact in unresectable metastatic colorectal cancer	6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	6
Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review	6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	6
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	6
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	6
Integrating PET/CT into breast cancer care: a review of recent developments	6
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	6
Is the ketogenic diet still controversial in cancer treatment?	6
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	6
The optimal management of brain metastases from gestational trophoblastic neoplasia	6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?	6
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation	5
The role of planetary health in urologic oncology	5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
Recent advances in the management of intrahepatic cholangiocarcinoma: the role of actionable mutations and targeted therapies	5
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective	5
Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis	5
Cancer immunotherapy efficacy and machine learning	5
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?	5
Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges	5
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches	5
Relugolix in the management of prostate cancer	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens	5
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	5
Desmoplastic small round cell tumor: from state of the art to future clinical prospects	5
Toward clinical translation of AI-Led drug discovery in endometrial cancer	5
Surgical management of intrahepatic cholangiocarcinoma	5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators	5

The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management	4
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized cont	4
A meta-analysis of UCA1 accuracy in the detection of bladder cancer	4
Understanding the link between aspartame and cancer	4
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer	4
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	4
G-CSF for managing venetoclax-related neutropenia in acute myeloid leukemia	4
The effect of mechanical force in genitourinary malignancies	4
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?	4
Avelumab in locally advanced or metastatic urothelial carcinoma	4
Therapeutic options in thymomas and thymic carcinomas	4
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database	4
Current and emerging treatment options for BRAFV600-mutant melanoma	4
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma	4
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis	4
Implementation of a CAR-T cell therapy program in India	4
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	4
Treatment of cervical cancer: overcoming challenges in access to brachytherapy	4
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma	4
Targeted therapies in advanced biliary malignancies: a clinical review	4
Advances and future directions in radiopharmaceutical delivery for cancer treatment	4
Immune checkpoint inhibitors for recurrent endometrial cancer	4
Burden trends and risk factors for prostate cancer from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021	4
Clear cell sarcoma: state-of-the art and perspectives	4
RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway	4
Factors influencing survival in metastatic castration-resistant prostate cancer therapy	4
The multidisciplinary management of locally advanced rectal cancer	4
Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes	4
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer	4
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis	4
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment	4
How do non-coding RNAs impact treatment regimens currently being used in AML?	4
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial	4
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	4
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges	4
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care	4
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	4
How can we address the challenge of distant metastases in HNSCC prognosis?	4
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement	3
Medullary thyroid carcinoma	3
Advancing patient-centered care in myelodysplastic syndromes/neoplasms with oral therapies	3
Melanoma neoadjuvant treatment: review and update of recent trials	3
Implementing machine learning to predict survival outcomes in patients with resected pulmonary large cell neuroendocrine carcinoma	3
Current usage of pembrolizumab in triple negative breast cancer (TNBC)	3
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab	3
Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what’s new in 2025?	3
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma	3
Current androgen receptor antagonists under investigation for resistant prostate cancer	3
Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer	3
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	3
Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma	3
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	3
The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis	3
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment	3
Opportunities and challenges in the clinical application of anticancer virotherapy	3
Novel therapies for metastatic prostate cancer	3
Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives	3
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes	3
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors	3
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis	3
Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database	3
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy	3
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis	3
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies	3
Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis	3
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors	3
Integrating supportive care into the multidisciplinary management of lung cancer: we can’t wait any longer	3
Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review	3
Increasing the accuracy of colorectal cancer screening	3
Overview and recent advances in incidental meningioma	3
Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis	3
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions	3
Hot topics in renal cancer pathology: implications for clinical management	3
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review	3
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis	3
Re-irradiation for recurrent/progressive pediatric brain tumors: from radiobiology to clinical outcomes	3
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a system	3
Established and emerging biomarkers approaches in urothelial carcinoma	2
Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity	2
Myeloid cell leukemia-1 as a candidate prognostic biomarker in cancers: a systematic review and meta-analysis	2
Maintenance therapy in patients with unresectable metastatic colorectal cancer receiving oxaliplatin plus antiangiogenic-based induction regimen: a study cohorts analysis	2
Targeting the DNA damage response in pediatric malignancies	2
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review	2
The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data	2
Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: is the era of interventional theranostics next?	2
Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma	2
Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma	2
Ifosfamide-induced nephrotoxicity in oncological patients	2
The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer	2
A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022	2
2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma	2
Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma	2
Why has targeting EGFR aberrations in glioblastoma therapy had limited success?	2
An update understanding of stemness and chemoresistance of prostate cancer	2
The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research	2